Ulrika Simonsson is a professor in pharmacokinetics, leading her own independent research group focusing on pre-clinical to clinical pharmacokinetic-pharmacodynamic translation and its relation to drug development.
Keywords: antibiotic resistance ehealth machine learning pharmacokinetics pharmacometrics pharmacodynamics therapeutic drug monitoring tuberculosis translational medicine non-linear mixed effects modeling modeling and simulation artifical intelligence
Prof Simonsson is a professor of pharmacokinetics at the Department of Pharmaceutical Biosciences at Uppsala University in Sweden. She holds a Masters in Pharmaceutical Sciences, is a licensed pharmacist and obtained a PhD in Pharmaceutical Sciences from Uppsala University in 2000 focusing on pharmacokinetics and pharmacodynamics. She did her post doc work with Pharsight Coperation, CA, USA in 2001-2002 and was on sabbatical leave during 2004-2006 from her faculty position while working as a principal scientist at Astrazeneca. In 2010 she became Associate Professor (docent) and full Professor in Pharmacokinetics in 2016. In 2004 she received the AstraZeneca’s Young Talented Scientist award, in 2007 AstraZenceca’s Clinical Innovation award and in 2011, a Grant for Promotion to Professor from Uppsala University.
Her expertise is focused on how modeling and simulation of pharmacokinetics (PK) and pharmacodynamics (PD) can be used to translate pre-clinical information from in vitro and in vivo to predictions of human exposure and efficacy in order to optimize drug development and for defining individualized dosing.
She has received large EU grants within the field of tuberculosis and was the lead for modeling and simulation in the European IMI funded consortium Predict-TB. She has supervised 15 students to their Ph.D., six of these as the main supervisor. Ulrika has acted as an international opponent at two doctoral theses, has published more than 90 peer-reviewed research articles and is routinely giving training to academia and industry. She has almost 25 years of experience as a pharmacometric external consultant to many drug development companies including regulatory interactions and filing. She has been the pharmacometric lead on two successful registrations and several Phase III filings. Her research and consultancy activities have included several different therapeutic areas such as malaria, tuberculosis, HIV, thrombosis/cardiovascular diseases, diabetes, insomnia, prostate cancer, hypertension, asthma and cortisol insufficiency. She has an extensive hands-on experience in modeling complex PKPD and disease models.
Professor Simonsson's research profile is presented at
Please contact the directory administrator for the organization (department or similar) to correct possible errors in the information.